HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
4-desacetylvinblastine hydrazide
Also Known As:
4-DAVLB-HY; 4-deacetylvinblastine hydrazide; 4-desacetylvinblastine-3-carboxhydrazide; DAVLBHYD; desacetylvinblastine-3-carboxylic acid hydrazide
Networked:
7
relevant articles (
1
outcomes,
2
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Heterocyclic Compounds: 198
Alkaloids: 5398
Indole Alkaloids: 200
Secologanin Tryptamine Alkaloids: 81
Vinca Alkaloids: 463
Vinblastine: 3373
4-desacetylvinblastine hydrazide: 7
Fused-Ring Heterocyclic Compounds
2-Ring Heterocyclic Compounds
Indoles: 200
Indole Alkaloids: 200
Secologanin Tryptamine Alkaloids: 81
Vinca Alkaloids: 463
Vinblastine: 3373
4-desacetylvinblastine hydrazide: 7
Indolizines: 3
Indolizidines: 2
Indole Alkaloids: 200
Secologanin Tryptamine Alkaloids: 81
Vinca Alkaloids: 463
Vinblastine: 3373
4-desacetylvinblastine hydrazide: 7
Related Diseases
1.
Neoplasms (Cancer)
03/15/1990 - "
In human tumor nude mouse xenograft studies, L/1C2-DAVLBHYD antitumor activity was superior to that seen with free drug, free antibody, mixtures of free drug and free antibody, or control DAVLBHYD conjugates prepared with non-tumor-binding IgGs.
"
09/01/1993 - "
Efficacy increased from moderate tumor growth inhibition by using free 4-desacetylvinblastine-3-carboxhydrazide to tumor regression and long-term stabilization with the ADC system.
"
03/15/1990 - "
In studies using six different human tumor xenografts, the level of potency of L/1C2-DAVLBHYD was related to L/1C2 antigen expression, although the growth rate probably also contributes to the conjugate sensitivity of the tumors.
"
07/01/1995 - "
In contrast to the DAVLBHYD results, ADC delivery of doxorubicin did not regress tumors, but did result in a substantial increase in the MTD.
"
06/15/1990 - "
The activity of the conjugate of monoclonal antibody KS1/4 with 4-desacetylvinblastine-3-carboxhydrazide (KS1/4-DAVLB-HY) was explored in the OVCAR-3 human ovarian xenograft tumor model.
"
2.
Squamous Cell Carcinoma (Epidermoid Carcinoma)
06/15/1987 - "
The human squamous carcinoma-reactive murine monoclonal antibody PF1/D was used to derive a conjugate with the Vinca derivative 4-desacetylvinblastine-3-carboxyhydrazide (PF1/D-DAVLBHYD).
"
06/15/1987 - "
When tested in vivo in a 3-day-established human squamous carcinoma nude mouse xenograft model, the PF1/D-DAVLBHYD conjugate eliminated tumor growth with three injections (days 3, 6, and 9) at 2 mg/kg Vinca content.
"
01/01/1988 - "
An immunoconjugate (PF1/D-DAVLBHYD), made with the squamous carcinoma reactive monoclonal antibody PF1/D and a derivative of vinblastine, DAVLBHYD, was shown to suppress established T222 human tumor nude mouse xenografts using a multidose protocol.
"
3.
Carcinoma (Carcinomatosis)
07/01/1995 - "
In the current study the ability of the system to deliver doxorubicin was tested in MCF7 breast carcinoma xenografts and OVCAR3 ovarian carcinoma xenografts, and in T380 and LS174T colon tumor xenografts for comparison with previous DAVLBHYD results.
"
4.
Breast Neoplasms (Breast Cancer)
07/01/1995 - "
In the current study the ability of the system to deliver doxorubicin was tested in MCF7 breast carcinoma xenografts and OVCAR3 ovarian carcinoma xenografts, and in T380 and LS174T colon tumor xenografts for comparison with previous DAVLBHYD results.
"
5.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/01/1995 - "
Using CCRF-CEM, a human acute lymphoblastic leukemia cell line, as a target in this assay, we observed a greater than 90% increase in cell viability using 100 micrograms/ml 27.8.1A with a 0.1 microgram/ml concentration of DAVLBHYD.
"
Related Drugs and Biologics
1.
Doxorubicin (Adriamycin)
2.
Antigens
3.
Monoclonal Antibodies
4.
Immunoconjugates (Immunoconjugate)
5.
Vinblastine (Vinblastine Sulfate)
6.
Immunoglobulin G (IgG)
Related Therapies and Procedures
1.
Injections
2.
Therapeutics